Skip to content
10-Q

Quarterly Report

Vera Therapeutics, Inc. VERA

0001193125-26-212143

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 71.78M sh
Shares Diluted Q1 2026 · Mar 31, 2026 71.48M sh
Shares Diluted Q1 2026 · Mar 31, 2025 63.67M sh
Capex Q1 2026 · Mar 31, 2026 $23K
Capex Q1 2026 · Mar 31, 2025 $187K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$106.5M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$54.41M
Long Term Debt Q1 2026 · Mar 31, 2026 $75.03M
Long Term Debt Q1 2026 · Dec 31, 2025 $74.84M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $114.35M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $354.73M
Stockholders Equity Q1 2026 · Mar 31, 2026 $499.7M
Stockholders Equity Q1 2026 · Dec 31, 2025 $604.52M
Stockholders Equity Q1 2026 · Mar 31, 2025 $535M
Stockholders Equity Q1 2026 · Dec 31, 2024 $577.16M
Current Liabilities Q1 2026 · Mar 31, 2026 $45.15M
Current Liabilities Q1 2026 · Dec 31, 2025 $53.46M
Total Liabilities Q1 2026 · Mar 31, 2026 $122.04M
Total Liabilities Q1 2026 · Dec 31, 2025 $130.21M
Current Assets Q1 2026 · Mar 31, 2026 $615.8M
Current Assets Q1 2026 · Dec 31, 2025 $728.88M
Total Assets Q1 2026 · Mar 31, 2026 $621.74M
Total Assets Q1 2026 · Dec 31, 2025 $734.73M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.69
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.81
Eps Basic Q1 2026 · Mar 31, 2026 −$1.69
Eps Basic Q1 2026 · Mar 31, 2025 −$0.81
Sga Expense Q1 2026 · Mar 31, 2026 $39.12M
Sga Expense Q1 2026 · Mar 31, 2025 $15.92M
Rd Expense Q1 2026 · Mar 31, 2026 $86.01M
Rd Expense Q1 2026 · Mar 31, 2025 $41.28M
Net Income Q1 2026 · Mar 31, 2026 −$121.03M
Net Income Q1 2026 · Mar 31, 2025 −$51.69M
Operating Income Q1 2026 · Mar 31, 2026 −$125.13M
Operating Income Q1 2026 · Mar 31, 2025 −$57.19M